- Home
- NODK vs REVBW Comparison
NODK vs REVBW Comparison
Compare NODK & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- REVBW
- Stock Information
- Founded
- NODK 1946
- REVBW N/A
- Country
- NODK United States
- REVBW United States
- Employees
- NODK N/A
- REVBW 9
- Industry
- NODK Property-Casualty Insurers
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- REVBW Health Care
- Exchange
- NODK Nasdaq
- REVBW Nasdaq
- Market Cap
- NODK N/A
- REVBW N/A
- IPO Year
- NODK 2017
- REVBW 2020
- Fundamental
- Price
- NODK $12.96
- REVBW $0.02
- Analyst Decision
- NODK
- REVBW
- Analyst Count
- NODK 0
- REVBW 0
- Target Price
- NODK N/A
- REVBW N/A
- AVG Volume (30 Days)
- NODK 20.8K
- REVBW N/A
- Earning Date
- NODK 05-08-2025
- REVBW N/A
- Dividend Yield
- NODK N/A
- REVBW N/A
- EPS Growth
- NODK N/A
- REVBW N/A
- EPS
- NODK N/A
- REVBW N/A
- Revenue
- NODK $325,204,000.00
- REVBW N/A
- Revenue This Year
- NODK N/A
- REVBW N/A
- Revenue Next Year
- NODK N/A
- REVBW N/A
- P/E Ratio
- NODK $41.71
- REVBW N/A
- Revenue Growth
- NODK 6.97
- REVBW N/A
- 52 Week Low
- NODK $12.83
- REVBW N/A
- 52 Week High
- NODK $17.24
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- NODK 34.85
- REVBW N/A
- Support Level
- NODK $12.83
- REVBW N/A
- Resistance Level
- NODK $13.37
- REVBW N/A
- Average True Range (ATR)
- NODK 0.38
- REVBW 0.00
- MACD
- NODK -0.09
- REVBW 0.00
- Stochastic Oscillator
- NODK 7.88
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).